Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.
Provider organizations are using generative AI for all sorts of use cases. It’s delivering impressive returns in two—tech support and patient experience.
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
Last month, the Department of Commerce launched an investigation into the importing of such items, seeking to determine the impact on national security.
Authorities granted 510(k) clearance for Brain Health in late September, with the Los Angeles-based imaging center operator touting the decision Tuesday.
When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device.
Experts recently developed a new set of recommendations to help providers better navigate decisions related to contrast administration, sharing their guidance in Insights into Imaging.
Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
